Analyst Christian Glennie from Stifel Nicolaus reiterated a Buy rating on Hikma Pharmaceuticals (HIK – Research Report) and keeping the ...

London, United Kingdom – Hikma Pharmaceuticals PLC (Hikma ... We closed the Xellia acquisition in September and expect a revenue contribution of around $20 million this year, in line with previously ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

If you're interested in exploring more stocks under $20 get an edge over other traders with Benzinga Pro while we're currently offering a 14-day trial. Stocks under $20 offer investors and ...

Terms may apply to offers listed on this page. Home buyers and lenders sometimes overlook 20-year mortgages, preferring the more popular 15- and 30-year loans. But for certain home buyers ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

Dividend amount and dividend per share are quoted in the currency of the stock selected. Please note that past performance is not a reliable indicator of future returns. Important Information Please ...

Note :Financial Information is based on consolidated numbers.

Auto parts maker Magna International sees quarterly net income hit US$328 million ...

USFDA approves Crofelemer 125 mg delayed-release tablets for the symptomatic relief of diarrhea in patients with HIV/AIDS on anti-retroviral therapy (ART). -Glenmark Generics receives ANDA ...

Hikma Pharmaceuticals PLC develops, manufactures and markets a broad range of branded and non-branded generic pharmaceutical products across the US, the MENA region, and Europe.